David O'Malley, MD

David M. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the Ohio State University Comprehensive Cancer Center, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab (Avastin) as treatment of patients with platinum-agnostic ovarian cancer.

In the overall study population of 60 patients, the overall response rate (ORR) was 50%. Looking at it at the high expression folate receptor group, which accounted for half of the patient population versus the low expression folate receptor, the ORR is even more pronounced 64%, in the high folate receptor alpha cohort. When platinum sensitivity versus platinum resistance was assessed in the high expression folate receptor alpha group, the ORR was 69% versus 59%, respectively.

O’Malley states that what is even more exciting about the data is that the duration of response (DOR) persisted beyond 12 months in patients with high expression folate receptor alpha who were platinum-sensitive and approached 10 months among those who were platinum-resistant. In the population of patients with median expression folate receptor alpha, the DOR was 8 months.

Further, 32 of the 33 patients who had high expression folate receptor alpha had tumor shrinkage, which O’Malley says represents the most impressive waterfall plot he has seen over time.

Videos

David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

Mirvetuximab Soravtansine Plus Bevacizumab Yields High Responses in Platinum-Agnostic Ovarian Cancer

David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

We now know there is a group of patients who will benefit remarkably from the use of PARP inhibitors, and that includes patients who have either a 

mutation, says O’Malley. Whenever a survival advantage is seen, we know it is going to be beneficial. It is clear now that this group of patients with

-mutant ovarian cancer will benefit from PARP inhibitors, and they should receive these therapies earlier on.

There are 3 PARP inhibitors now available in the treatment landscape for ovarian cancer, with the most recent approval of niraparib (Zejula) in the frontline setting for adult patients who are in a complete or partial response to first-line platinum-based chemotherapy. According to O’Malley, PARP inhibitors should be given in the frontline setting for patients harboring a 

 mutation, but if they do not receive it in their first-line of therapy and receive a platinum instead, they should be receiving a PARP inhibitor in the platinum-sensitive, recurrent setting.

<< View more resources and information in ovarian cancer

David O'Malley, MD, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer

David O&rsquo;Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab (Avastin) plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.

There is still not enough data to say there is synergy between these 2 agents, but so far there has been an increase in progression-free survival (PFS) and response rates compared to standard cytotoxic chemotherapies.

David O&rsquo;Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.

David O'Malley, MD | Authors

Articles

Mirvetuximab Soravtansine Plus Bevacizumab Yields High Responses in Platinum-Agnostic Ovarian Cancer

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer

Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer